NFE2L2 and neoplasm: While it exhibits anti-tumor effects via succinate dehydrogenase (SDH) inhibition and Nrf2 pathway activation [56], concurrent suppression of type I interferon (IFN-I) responses may paradoxically facilitate tumor immune evasion [79].